Preclinical data highlights MRTX0902 and
MRTX1719 as potentially compelling targeted oncology treatment
options
SAN
DIEGO, April 3, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology
company, today announced a presentation demonstrating in
preclinical models the ability of MRTX0902, a selective and potent
SOS1 inhibitor, to enhance anti-tumor activity and overcome
acquired resistance in combination with either adagrasib, a
potent and selective KRASG12C inhibitor, or an epidermal
growth factor receptor (EGFR) inhibitor (e.g.
osimertinib).
Findings will be presented on April
17 at the American Association for Cancer Research (AACR
2023) Annual Congress as an oral presentation at 3:36 p.m. -3:51 p.m. ET / 12:36 p.m.- 12:51 p.m. PT (Presentation #3499)
during the Molecular Pathway Discovery and Translation in Solid
Tumors mini session. The full abstract for the presentation can be
found here.
In addition, Mirati will share poster presentations featuring
MRTX1719, the company's novel MTA cooperative PRMT5 inhibitor.
These posters highlight the mechanism by which MRTX1719 elicits
potent and selective synthetic lethality in MTAP deleted tumors as
well as the further enhancement of antitumor activity via rational
targeted combination strategies (Posters #2778/1 and 2779/2).
Posters can be viewed on April 17
from 1:30 p.m. - 5:00 p.m. ET/
10:30 a.m. - 2:00 p.m. PT during the
Experimental and Molecular Therapeutics Session and will be
available here.
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a commercial stage biotechnology
company whose mission is to discover, design and deliver
breakthrough therapies to transform the lives of patients with
cancer and their loved ones. The company is relentlessly focused on
bringing forward therapies that address areas of high unmet need,
including lung cancer, and advancing a pipeline of novel
therapeutics targeting the genetic and immunological drivers of
cancer. Unified for patients, Mirati's vision is to unlock the
science behind the promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us
on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes forward-looking statements regarding
Mirati's business, financial guidance and the therapeutic and
commercial potential of KRAZATI® (adagrasib),
sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative
PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133
(selective KRASG12D inhibitor), Mirati's technologies and Mirati's
other products in development. Any statement describing Mirati's
goals, expectations, intentions or beliefs, financial or other
projections, is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, including those related to the
impact COVID-19 could have on our business, and including those
inherent in the process of discovering, developing and
commercializing medicines that are safe and effective for use as
human therapeutics, and in the endeavor of building a business
around such medicines.
Mirati's forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its
results to differ materially from those expressed or implied by
such forward-looking statements. Although Mirati's forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Mirati. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning
Mirati's programs are described in additional detail in Mirati's
annual report on Form 10-K, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission and available at
the SEC's Internet site (www.sec.gov). These forward-looking
statements are made as of the date of this press release, and
Mirati assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-to-present-research-at-the-aacr-annual-congress-for-two-potentially-first-in-class-clinical-stage-programs-301788788.html
SOURCE Mirati Therapeutics, Inc.